Latest News for: emas

Edit

Phenylketonuria Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, ...

GetNews 23 Aug 2025
elveInsight’s, “Phenylketonuria Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Phenylketonuria pipeline landscape ... Dive into DelveInsight's comprehensive report today! @ ... .
Edit

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ...

GetNews 23 Aug 2025
It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products ... It further highlights the inactive pipeline products in this space ... On 17 August 2025, Curis Inc ... Ascentage Pharma ... Email.
Edit

Myocardial Infarction Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 23 Aug 2025
DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape ... Faraday Pharmaceuticals ... Glenzocimab ... Email.
Edit

Advanced Melanoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 23 Aug 2025
DelveInsight’s, “Advanced Melanoma Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape ... On 22 August 2025, H ... Replimune ... IO102-IO103 ... BNT111.
Edit

Gold Price Outlook – Gold Continues to Sit Near 50 Day EMA

FX Empire 22 Aug 2025
The gold market continues to see a ...
Edit

Chronic Refractory Cough Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 22 Aug 2025
It covers the pipeline drug profiles, including clinical and nonclinical stage products ... Click here ....
Edit

Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, ...

GetNews 22 Aug 2025
It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products ... Click here ....
Edit

Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape ... HSK31858 ... CSL 787.
Edit

Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape ... Merck Sharp & Dohme ... Email.
Edit

Diabetic Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Diabetic Nephropathy Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape ... On 11 August 2025, Inversago Pharma Inc ... City.
Edit

SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape ... Email.
Edit

Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, ...

GetNews 22 Aug 2025
DelveInsight’s, “Spasticity Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape ... and others ... Spasticity Emerging Drugs Profile MTR-601. Motric Bio.
Edit

JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 22 Aug 2025
DelveInsight’s, “JAK Inhibitor Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in JAK Inhibitor pipeline landscape ... Discover how the JAK Inhibitor treatment paradigm is evolving ... NV.
Edit

Recurrent Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape ... Ascletis ... GX-I7. Genexine ... Olinvacimab ... VXM01.
Edit

Heart Failure Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 22 Aug 2025
DelveInsight’s, “Heart Failure Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape ... The study will last for about 60 weeks ... Mesoblast ... HU 6 ... Email.

Article Search

tools
×
×
×
×